| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2434303A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | CA2418173A1 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/23/2003 | CA2417156A1 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277730A1 Neovascularization inhibitors |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1277466A1 Patch containing anti-inflammatory agent |
| 01/22/2003 | EP1277057A2 Screening method for compounds |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276761A2 New bromodomain protein |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276742A2 Process for the preparation of pyrazolopyridine derivatives |
| 01/22/2003 | EP1276740A2 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276736A2 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| 01/22/2003 | EP1276729A1 New neurokinin antagonists for use as medicaments |
| 01/22/2003 | EP1276726A2 Substituted phenyl farnesyltransferase inhibitors |
| 01/22/2003 | EP1276722A1 Naphthamidine urokinase inhibitors |
| 01/22/2003 | EP1276717A2 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276713A1 Inhibition of angiogenesis and tumor growth |
| 01/22/2003 | EP1276498A1 Use of npy y1 receptor antagonists in the treatment of inflammatory conditions |
| 01/22/2003 | EP1276495A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 01/22/2003 | EP1276488A1 Use of lactic acid bacterium for the treatment of peritonitis |
| 01/22/2003 | EP1276487A1 Treatment of conditions of the central nervous system using mycobacteria |
| 01/22/2003 | EP1276486A2 Joint repair using mesenchymal stem cells |
| 01/22/2003 | EP1276462A2 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1030835B1 Urea derivatives and their use as integrin inhibitors |
| 01/22/2003 | EP0898562B1 Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
| 01/22/2003 | EP0865339B1 Metalloproteinase inhibitors |
| 01/22/2003 | EP0828728B1 Phenyl dihydrobenzofuranes |
| 01/22/2003 | CN1392796A Polyhydroxylated benzene-containing compounds |
| 01/22/2003 | CN1392158A Pentadeca-peptide capable of specifically binding with intercellular adhesion molecule-1 |
| 01/22/2003 | CN1391932A Waist recovery plaster |
| 01/22/2003 | CN1391930A External medicine for curing gynaecological imflammation and its preparing method |
| 01/22/2003 | CN1391927A Medicine for curing rheumatism and rheumatoid arthritis |
| 01/22/2003 | CN1391926A Medicine for curing various pains |
| 01/22/2003 | CN1391912A Kidney invigorating and bone strengthening medicine and its preparing method |
| 01/22/2003 | CN1099462C Medical composition |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/22/2003 | CN1099288C Pharmaceutical composition for treating inflammtory bowel diseases |
| 01/22/2003 | CN1099285C Novel anti-spasmodic and anti-inflammatory agent composition and its process for manufacturing |
| 01/21/2003 | US6509468 FR 173657 used as an antiallergen, antiinflammatory agent, antishock agent, or analgesic; autoimmune diseases |
| 01/21/2003 | US6509369 Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids |
| 01/21/2003 | US6509366 Substituted imidazoles as selective modulators of Bradykinin B2 receptors |
| 01/21/2003 | US6509365 Useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs. |
| 01/21/2003 | US6509364 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2α antagonists |
| 01/21/2003 | US6509363 P38 is a mitogen-activated protein kinase; pyrrole, oxazole, thiazole, and imidazole derivatives |
| 01/21/2003 | US6509353 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 01/21/2003 | US6509352 Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509346 Chemokine receptor antagonists and methods of use therefor |
| 01/21/2003 | US6509329 Cyclic diamine compound with 6-membered ring groups |
| 01/21/2003 | US6509328 Glutamate receptor antagonists |
| 01/21/2003 | US6509318 TGF-B inhibitors and methods |
| 01/21/2003 | US6509313 Stimulation of immune response with low doses of cytokines |
| 01/21/2003 | US6509165 Detecting the ability of proinsulin peptide to preferentially stimulate the T-cells of diabetic subjects by measuring the ability of the T-cells to proliferate or ability of the T-cells to produce cytokines |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/21/2003 | CA2231195C Sustained release matrix for high-dose insoluble drugs |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | WO2002006214A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415954A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/16/2003 | WO2003005036A2 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | WO2003005035A1 Chp for use as marker for sepsis-type inflammatory diseases |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004497A1 Novel heterocyclic compound |
| 01/16/2003 | WO2003004495A1 Novel immunomodulating compounds |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004473A1 Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004460A2 Succinic acid derivatives |
| 01/16/2003 | WO2003004454A1 Linked cyclitols and their polysulfated derivatives |
| 01/16/2003 | WO2003004451A1 Hydroxybuttersäureester von acetylsalicylic acid, their methods of production and application as well as drugs containing them |
| 01/16/2003 | WO2003004098A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | WO2003004065A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 01/16/2003 | WO2003004060A1 Compositions and preparation methods for bioavailable oral aceaceclofenac dosage forms |
| 01/16/2003 | WO2003004049A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 01/16/2003 | WO2003004042A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 01/16/2003 | WO2003004038A1 Topically-applied composition based on ammonium hydroxide |
| 01/16/2003 | WO2003004032A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004031A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |